Actualités quotidiennes

Indicative seller‑declared price ranges for Natural Extracts & Herbal Ingredients, based on platform listings.

A completed study evaluates immunoglobulin dosage in CIDP and MMN patients. The study compares IVIG and SCIG treatments.

The UK MHRA released several Field Safety Notices between 10‑14 August 2026, detailing safety concerns and required actions for affected drugs and devices.

Dräger has broadened its Field Safety Notice to include more Atlan anaesthesia workstations after identifying a manufacturing defect that may cause ventilator failure.

The UK Medicines and Healthcare products Regulatory Agency released a series of Field Safety Notices between 20 and 24 July 2026, outlining safety actions for several medicines and devices.

Neuraxpharm UK Ltd reported missing safety information in the Patient Information Leaflet and Summary of Product Characteristics for certain batches of Tuzulby prolonged‑release 20 mg, 30 mg and 40 mg tablets.

Macarthys Laboratories (Martindale Pharma) reported to the MHRA that several batches of Xaggitin XL prolonged‑release tablets contain incorrect tablet counts, prompting a defect notification.

The MHRA released Field Safety Notices covering several medicines and devices between 6 and 10 July 2026.

Becton Dickinson UK Ltd is recalling batches of ChloraPrep 2%/70% cutaneous solution 1 mL applicators due to a potential sterility breach in packaging.

Bristol Laboratories Limited is recalling batch 7124002 of Phenoxymethylpenicillin 250 mg/5 ml sugar‑free oral solution due to labeling issues.

Relonchem Limited notified the MHRA of particle presence in some Gabapentin Relonchem 50 mg/ml oral solution bottles after a customer complaint.

The UK Medicines and Healthcare products Regulatory Agency released a series of Field Safety Notices between 22 and 26 June 2026, highlighting safety actions for several medicines and medical devices.